---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-24-014278"
form_type: "8-K"
ticker: "PCSA"
cik: "0001533743"
company_name: "Processa Pharmaceuticals, Inc."
filed_at: "2024-04-11T23:59:59+00:00"
generated_at: "2026-06-04T00:01:27.120711+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "medium"
source: SEC EDGAR
---

# Processa presents NGC-Cap Phase 1b data at AACR; poster modified

## Summary
- David Young, President R&D, presented two abstracts at AACR 2024 on NGC-Cap and Project Optimus.
- NGC-Cap Phase 1b data shows significantly increased 5-FU exposure and improved safety vs capecitabine.
- The originally presented poster was subsequently modified; amended posters posted on company website.
- Second abstract addresses optimal dose using Phase 1 and preclinical data under Project Optimus.
- No specific numerical results disclosed in filing; detailed data available in website publications.

## SEC filing metadata
- accession: 0001493152-24-014278
- form_type: 8-K
- ticker: PCSA
- cik: 0001533743
- company_name: Processa Pharmaceuticals, Inc.
- filed_at: 2024-04-11T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: medium
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1533743/000149315224014278/0001493152-24-014278-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1533743/000149315224014278/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-24-014278
- JSON: https://secwatch.observer/filing/0001493152-24-014278.json
- Plain text: https://secwatch.observer/filing/0001493152-24-014278.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.